<p>美國總統選舉將於 2024 年 11 月 5 日舉行，但在選舉之前，投資者可能還想關注另一個事件。從 11 月 3 日至 11 月 6 日，肥胖學會將舉行其年度會議，ObesityWeek 2024。<strong>Viking Therapeutics Inc. NASDAQ: VKTX</strong> 將是一個重要的演講者。</p>
<p>Viking 將提供其主要候選藥物 VK2735 雙重 GLP-1/GIP 激動劑的進展更新。該公司的注射藥物正在對肥胖患者進行的第二階段 VENTURE 研究中，經過 13 周的治療後進行了評估。這個領域競爭日益激烈，但 Viking 的候選藥物產生了多個數據點，顯示出與 <strong>Novo Nordisk A/S NYSE: NVO</strong> 和 <strong>Eli Lilly &amp; Co. NYSE: LLY</strong> 的候選藥物相似，甚至更好的減重效果。</p>
<p>獲取 <strong>Viking Therapeutics</strong> 的提醒：</p>
<p>然而，真正讓投資者感到興奮的是該公司的 VK2735 口服版本。這種藥物每天服用一次，持續 28 天，目前正在進行第一階段的多次遞增劑量（MAD）臨牀試驗。</p>
<h2><strong>短期和長期的理由是相同的</strong></h2>
<p>沃倫·巴菲特曾説，本傑明·格雷厄姆創造了 “在短期內，市場是一個投票機……” 這一説法。該聲明背後的情感是，股票在短期內上漲所需的只是資金，而不是任何特定的洞察力，或者如格雷厄姆所説的，“情緒穩定性”。</p>
<p>這讓我想起了一個營銷口號。也就是説，人們是基於情感購買，然後用事實來證明。而且，這種情況在股票中經常發生。</p>
<p>然而，該聲明的第二部分是，“……但從長遠來看，市場是一個稱重機。” 這意味着，隨着時間的推移，公司通過增加收入、盈利，甚至可能的分紅來證明自己，股票因其價值而上漲。</p>
<p>Viking Therapeutics 尚未達到這一階段。這仍然是一家處於臨牀階段的無收入公司。即使公司發佈強勁的報告，目前也預計到 2027 年 VK2735 的注射形式才能商業化。</p>
<p>儘管公司擁有約 10 億美元的現金以支持其藥物通過試驗階段，但它可能需要找到一個合作伙伴來大規模生產該藥物。但這並不意味着沒有事實可以證明你購買 VKTX 股票的合理性。</p>
<h2><strong>VKTX 股票的看漲理由</strong></h2>
<p>Viking Therapeutics 在過去 12 個月中表現出色，股價上漲超過 691%。這可能讓一些投資者擔心 VKTX 股票處於狂熱階段。但有幾個理由相信未來仍有更多上漲空間。</p>
<ul>
<li>
<p>正如你在過去 18 個月中看到的，減重市場巨大且正在增長。<strong>高盛集團 NYSE: GS</strong> 的分析師預測，該市場將從 400 億美元增長到 2030 年的 1300 億美元。這為多個競爭者留下了足夠的空間。</p>
</li>
<li>
<p>口服 GLP-1 藥物可能會顯示出強烈的客户偏好。</p>
</li>
<li>
<p>分析師對 VKTX 股票維持 “買入” 評級，普遍目標價為 108.60 美元。這將是超過 50% 的漲幅。</p>
</li>
<li>
<p>該公司 76% 的股票由機構投資者持有。這將有助於減少對風險承受能力較低的投資者的波動。</p>
</li>
</ul>
<h2><strong>利用噪音為你所用</strong></h2>
<h3>Viking Therapeutics MarketRank™ 股票分析</h3>
<p><strong>整體 MarketRank™**** 第 84 百分位</strong></p>
<p>分析師評級 <strong>買入</strong></p>
<p>上漲/下跌 <strong>51.4% 上漲</strong></p>
<p>空頭頭寸水平 <strong>看跌</strong></p>
<p>股息強度 <strong>不適用</strong></p>
<p>環境評分 <strong>-0.88</strong></p>
<p>新聞情緒 **0.46</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWCZ2PTI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWCZ2PTI"/></p>
<p>**</p>
<p>內部交易 <strong>出售股份</strong></p>
<p>預計收益增長 <strong>下降</strong></p>
<p>查看完整分析</p>
<p>在過去五天中，兩名 Viking 內部人士出售了 VKTX 股票。這通常會導致一些賣出活動。果然，儘管在臨牀試驗結果公佈後 VKTX 股票上漲了 33%，但該股回落了約 9%。</p>
<p>但這並不是值得擔憂的事情。所有的銷售都是根據 10b5-1 交易計劃進行的，並在實際銷售發生前幾個月披露。</p>
<p>而且，隨着股票形成更高的低點，這可能是你能得到的最大回調。然而，如果看跌情緒加劇，你可能想把任何拋售視為買入機會。</p>
<p>→ 揭曉：NVIDIA 的 “秘密特許權” 計劃（來自市場背後）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIwNQ"/></p>
<h2>你現在應該投資 1000 美元在 Viking Therapeutics 嗎？</h2>
<p>在考慮 Viking Therapeutics 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Viking Therapeutics 並不在名單上。</p>
<p>雖然 Viking Therapeutics 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票的詳細信息</p>

Viking治療

<p>Viking Therapeutics 在減肥藥市場上正逐漸獲得關注，其主要候選藥物 VK2735 顯示出良好的效果。該公司將在 2024 年肥胖周（ObesityWeek 2024）上進行展示，重點介紹其注射劑和口服藥物形式。儘管是一家尚未盈利的公司，分析師仍對 VKTX 股票維持 “買入” 評級，預測其股價將上漲 50%。減肥市場預計將顯著增長，為競爭者提供了充足的機會。近期內部人士的減持並不令人擔憂，投資者可能會將任何下跌視為買入機會</p>

<p>The U.S. presidential election will be held on November 5, 2024, but there’s another event that investors may want to vote on before the election. From November 3 through November 6, the Obesity Society will hold its annual meeting, ObesityWeek 2024. <strong>Viking Therapeutics Inc. NASDAQ: VKTX</strong> will be a key presenter.</p>
<div class="lb-trans"><p>美國總統選舉將於 2024 年 11 月 5 日舉行，但在選舉之前，投資者可能還想關注另一個事件。從 11 月 3 日至 11 月 6 日，肥胖學會將舉行其年度會議，ObesityWeek 2024。<strong>Viking Therapeutics Inc. NASDAQ: VKTX</strong> 將是一個重要的演講者。</p>
</div><p>Viking will provide updates on its lead candidate's progress, VK2735 dual GLP-1/GIP agonist drug. The company’s injectable drug is in a Phase 2 VENTURE study with obese patients who have been evaluated after 13 weeks of treatment. This is an increasingly crowded field, but Viking’s candidate has generated several data points that show similar, if not better, weight loss to candidates from <strong>Novo Nordisk A/S NYSE: NVO</strong> and <strong>Eli Lilly &amp; Co. NYSE: LLY</strong>.</p>
<div class="lb-trans"><p>Viking 將提供其主要候選藥物 VK2735 雙重 GLP-1/GIP 激動劑的進展更新。該公司的注射藥物正在對肥胖患者進行的第二階段 VENTURE 研究中，經過 13 周的治療後進行了評估。這個領域競爭日益激烈，但 Viking 的候選藥物產生了多個數據點，顯示出與 <strong>Novo Nordisk A/S NYSE: NVO</strong> 和 <strong>Eli Lilly &amp; Co. NYSE: LLY</strong> 的候選藥物相似，甚至更好的減重效果。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Viking Therapeutics</strong> 的提醒：</p>
</div><p>However, what is really causing investors to get excited is the company’s oral version of VK2735. The drug, which is dosed daily for 28 days, is in a Phase 1 multiple ascending dose (MAD) clinical trial.</p>
<div class="lb-trans"><p>然而，真正讓投資者感到興奮的是該公司的 VK2735 口服版本。這種藥物每天服用一次，持續 28 天，目前正在進行第一階段的多次遞增劑量（MAD）臨牀試驗。</p>
</div><h2><strong>The Short-Term and Long-Term Case Are the Same</strong></h2>
<div class="lb-trans"><h2><strong>短期和長期的理由是相同的</strong></h2>
</div><p>Warren Buffett said that Benjamin Graham coined the phrase, “In the short term, the market is a voting machine ...” The sentiment behind the statement is that all it takes for a stock to go up in the short term is money, not any particular insight or, as Graham said, “emotional stability.”</p>
<div class="lb-trans"><p>沃倫·巴菲特曾説，本傑明·格雷厄姆創造了 “在短期內，市場是一個投票機……” 這一説法。該聲明背後的情感是，股票在短期內上漲所需的只是資金，而不是任何特定的洞察力，或者如格雷厄姆所説的，“情緒穩定性”。</p>
</div><p>That reminds me of a marketing mantra. That is, people buy on emotion and then justify with facts. And all too frequently, that’s what happens with stocks.</p>
<div class="lb-trans"><p>這讓我想起了一個營銷口號。也就是説，人們是基於情感購買，然後用事實來證明。而且，這種情況在股票中經常發生。</p>
</div><p>However, the second part of that statement is, “...but in the long run, the market is a weighing machine.” This means that as time passes and companies prove themselves with increasing revenue, earnings, and perhaps dividends, stocks rise because of value.</p>
<div class="lb-trans"><p>然而，該聲明的第二部分是，“……但從長遠來看，市場是一個稱重機。” 這意味着，隨着時間的推移，公司通過增加收入、盈利，甚至可能的分紅來證明自己，股票因其價值而上漲。</p>
</div><p>Viking Therapeutics isn’t at that stage yet. This is still a pre-revenue, clinical-stage company. Even if the company delivers a strong report, it is currently targeting 2027 for when the injectable form of VK2735 will be commercially available.</p>
<div class="lb-trans"><p>Viking Therapeutics 尚未達到這一階段。這仍然是一家處於臨牀階段的無收入公司。即使公司發佈強勁的報告，目前也預計到 2027 年 VK2735 的注射形式才能商業化。</p>
</div><p>Although the company has approximately $1 billion in cash to get its drugs through the trial stage, it will likely need to find a partner to manufacture the drug at scale. But that doesn’t mean there aren’t facts to justify your purchase of VKTX stock.</p>
<div class="lb-trans"><p>儘管公司擁有約 10 億美元的現金以支持其藥物通過試驗階段，但它可能需要找到一個合作伙伴來大規模生產該藥物。但這並不意味着沒有事實可以證明你購買 VKTX 股票的合理性。</p>
</div><h2><strong>The Bullish Case for VKTX Stock</strong></h2>
<div class="lb-trans"><h2><strong>VKTX 股票的看漲理由</strong></h2>
</div><p>Viking Therapeutics has been one of the best-performing medical stocks in the last 12 months, with a gain of over 691%. That may make some investors concerned that VKTX stock is in the mania stage. But there are several reasons to believe there’s still more upside ahead.</p>
<ul>
<li>
<p>As you’ve seen in the last 18 months, the weight loss market is huge and is growing. Analysts from <strong>The Goldman Sachs Group NYSE: GS</strong> predict the market will grow from $40 billion to $130 billion in 2030. That leaves enough room for multiple competitors.</p>
</li>
<li>
<p>An oral GLP-1 drug is likely to show strong customer preference.</p>
</li>
<li>
<p>Analysts maintain a Buy rating on VKTX stock, with a consensus price target of $108.60. This would be a gain of over 50%.</p>
</li>
<li>
<p>76% of the company’s stock is owned by institutional investors. That will help smooth out volatility for less risk-tolerant investors.</p>
</li>
</ul>
<div class="lb-trans"><p>Viking Therapeutics 在過去 12 個月中表現出色，股價上漲超過 691%。這可能讓一些投資者擔心 VKTX 股票處於狂熱階段。但有幾個理由相信未來仍有更多上漲空間。</p>
<ul>
<li>
<p>正如你在過去 18 個月中看到的，減重市場巨大且正在增長。<strong>高盛集團 NYSE: GS</strong> 的分析師預測，該市場將從 400 億美元增長到 2030 年的 1300 億美元。這為多個競爭者留下了足夠的空間。</p>
</li>
<li>
<p>口服 GLP-1 藥物可能會顯示出強烈的客户偏好。</p>
</li>
<li>
<p>分析師對 VKTX 股票維持 “買入” 評級，普遍目標價為 108.60 美元。這將是超過 50% 的漲幅。</p>
</li>
<li>
<p>該公司 76% 的股票由機構投資者持有。這將有助於減少對風險承受能力較低的投資者的波動。</p>
</li>
</ul>
</div><h2><strong>Use the Noise to Your Advantage</strong></h2>
<div class="lb-trans"><h2><strong>利用噪音為你所用</strong></h2>
</div><h3>Viking Therapeutics MarketRank™ Stock Analysis</h3>
<div class="lb-trans"><h3>Viking Therapeutics MarketRank™ 股票分析</h3>
</div><p><strong>Overall MarketRank™****84th Percentile</strong></p>
<div class="lb-trans"><p><strong>整體 MarketRank™**** 第 84 百分位</strong></p>
</div><p>Analyst Rating<strong>Buy</strong></p>
<div class="lb-trans"><p>分析師評級 <strong>買入</strong></p>
</div><p>Upside/Downside<strong>51.4% Upside</strong></p>
<div class="lb-trans"><p>上漲/下跌 <strong>51.4% 上漲</strong></p>
</div><p>Short Interest Level<strong>Bearish</strong></p>
<div class="lb-trans"><p>空頭頭寸水平 <strong>看跌</strong></p>
</div><p>Dividend Strength<strong>N/A</strong></p>
<div class="lb-trans"><p>股息強度 <strong>不適用</strong></p>
</div><p>Environmental Score**-0.88**</p>
<div class="lb-trans"><p>環境評分 <strong>-0.88</strong></p>
</div><p>News Sentiment**0.46</p>
<div class="lb-trans"><p>新聞情緒 **0.46</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWCZ2PTI" alt="" original-src="https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx?Prefix=NASDAQ&amp;Symbol=VKTX&amp;v=2"/></p>
<p>**</p>
<div class="lb-trans"><p>**</p>
</div><p>Insider Trading<strong>Selling Shares</strong></p>
<div class="lb-trans"><p>內部交易 <strong>出售股份</strong></p>
</div><p>Proj. Earnings Growth<strong>Decreasing</strong></p>
<div class="lb-trans"><p>預計收益增長 <strong>下降</strong></p>
</div><p>See Full Analysis</p>
<div class="lb-trans"><p>查看完整分析</p>
</div><p>Over the past five days, two Viking insiders have sold shares of VKTX stock. This typically results in some selling activity, And sure enough, despite a 33% jump in VKTX stock after the clinical trial results were revealed, the stock has pulled back approximately 9%.</p>
<div class="lb-trans"><p>在過去五天中，兩名 Viking 內部人士出售了 VKTX 股票。這通常會導致一些賣出活動。果然，儘管在臨牀試驗結果公佈後 VKTX 股票上漲了 33%，但該股回落了約 9%。</p>
</div><p>But this isn’t something to be concerned about. All the sales were conducted as part of a Rule 10b5-1 trading plan and disclosed months before the actual sales took place.</p>
<div class="lb-trans"><p>但這並不是值得擔憂的事情。所有的銷售都是根據 10b5-1 交易計劃進行的，並在實際銷售發生前幾個月披露。</p>
</div><p>And with the stock forming higher lows, this may be about as big of a dip as you’ll get. However, if bearish sentiment picks up, you may want to look at any sell-off as a buying opportunity.</p>
<div class="lb-trans"><p>而且，隨着股票形成更高的低點，這可能是你能得到的最大回調。然而，如果看跌情緒加劇，你可能想把任何拋售視為買入機會。</p>
</div><p>→ Unveiled: NVIDIA’s &#34;Secret Royalty&#34; Program (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 揭曉：NVIDIA 的 “秘密特許權” 計劃（來自市場背後）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDIwNQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10205&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Viking Therapeutics right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Viking Therapeutics 嗎？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Viking Therapeutics 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Viking Therapeutics 並不在名單上。</p>
</div><p>While Viking Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Viking Therapeutics 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票的詳細信息</p>
</div>

Viking 治療股票：一個值得在選舉前考慮的投資機會